Monoclonal antibodies against pcbp-1 antigens, and uses therefor

Abstract

The present invention provides and includes monoclonal antibodies specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.

1 .- 34 . (canceled) 
     
     
         35 . A method of determining the status of a cell in a sample comprising:
 (a) obtaining said sample from a patient;   (b) contacting said sample with an antibody capable of preferentially detecting a soluble form of PCBP-1 antigen; and   (c) determining the quantity of said antigen.   
     
     
         36 . A method of determining the status of a cell in a sample comprising:
 (a) obtaining said sample from a patient;   (b) contacting said sample with an antibody capable of preferentially detecting a soluble form of PCBP-1 antigen; and   (c) determining the localization of said antigen.   
     
     
         37 . The method of  claim 36 , further comprising contacting said sample with an antibody capable of preferentially detecting a non-soluble form of PCBP-1 antigen. 
     
     
         38 . A method of determining the status of cell in a sample by:
 (a) obtaining said sample;   (b) contacting said sample with an antibody capable of preferentially detecting a soluble form of PCBP-1 antigen;   (c) determining quantity or localization of said antigen.   
     
     
         39 . A method according to  claim 38 , further comprising contacting said sample with an antibody capable of preferentially detecting a non-soluble form of PCBP-1 antigen. 
     
     
         40 .- 49 . (canceled)